Received Nov 10, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | 1 | — | LA |
The injection site turned red for about two weeks and then brownish; This is a spontaneous report received from a Consumer or other non HCP. A 57-year-old female patient received BNT162b2 omicron (lp.8.1) (COMIRNATY (2025-2026 FORMULA)), on 06Oct2025 as dose 1, single (Batch/Lot number: unknown) at the age of 57 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Celiac disease" (unspecified if ongoing); "hypothyroidism" (unspecified if ongoing); "anxiety" (unspecified if ongoing); "Only allergic to dust, mold and perfumes" (unspecified if ongoing). Concomitant medication(s) included: SYNTHROID; FLUOXETINE; CETIRIZINE; SHINGRIX taken for immunisation, on 17Sep2025 as dose 2, single. The following information was reported: VACCINATION SITE ERYTHEMA (non-serious) with onset 06Oct2025 at 18:00, outcome "recovered with sequelae" (21Oct2025), described as "The injection site turned red for about two weeks and then brownish". Therapeutic measures were not taken as a result of vaccination site erythema. The information on the batch/lot number for BNT162b2 omicron (lp.8.1) will be requested and submitted if and when received. Additional Information: The patient stated that the injection site turned red for about two weeks and then brownish. It was still discolored. The site was round and about two inches in diameter. When it was red, it was warm to touch. The patient did not had any meds for it.
Medical History/Concurrent Conditions: Anxiety; Celiac disease; Environmental allergy; Hypothyroidism
SYNTHROID; FLUOXETINE; CETIRIZINE